Cekdemir, D; Guvenc, S; Ozdemirkiran, F; Eser, A; Topts, T; Ozkocaman, V; Sahin, HH; Turak, EE; Esen, R; Comert, M; Sadrilo, S; Aslaner, M; Ulu, BU; Karakus, A; Bapur, DS; Alacacioglu, I; Aydin, D; Tekinalp, A; Namdaroglu, S; Ceran, F; Tarkun, P; Kiper, D; Cetiner, M; Yenerel, M; Demir, AM; Yilmaz, G; Terzi, H; Atilla, E; Malkan, UY; Acar, K; Ozturk, E; Tombak, A; Sunu, C; Salim, O; Alayvaz, N; Sayan, O; Ozan, U; Ayer, M; Gokgoz, Z; Andic, N; Kizilkilic, E; Noyan, F; Ozen, M; Tanrikulu, FP; Alanoglu, G; Ozkan, HA; Aslan, V; Cetin, G; Erikci, AA; Deveci, B; Dursun, FE; Dermenci, H; Aytan, P; Gunduz, M; Karakus, V; Ozlu, C; Demircioglu, S; Yanar, OMA; Ozatli, D; Undar, L; Tiftik, EN; Sucak, EGT; Haznedaroglu, I; Ozcan, M; Sencan, M; Tombuloglu, M; Ozet, G; Bilgir, O; Turgut, B; Ozcan, MA; Payzin, KB; Sonmez, M; Ayyildiz, E; Dal, MS; Ertop, S; Turgut, M; Soysal, T; Kaya, E; Unal, A; Pehlivan, M; Atagunduz, I; Firatli, TT; Saydam, G; Kucukkaya, RD
(2019)
Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP).